• Rola Khamisy-Farah, Eliyahu Fund, Shir Raibman-Spector, and Mohammed Adawi.
• Clalit Health Services, Akko, Israel.
• Isr Med Assoc J. 2021 Dec 1; 23 (12): 801-804.

BackgroundFibromyalgia syndrome (FMS) is a chronic disorder characterized by widespread musculoskeletal pain accompanied by various additional symptoms. The prevalence of FMS ranges between 2-8% of the population. The exact pathophysiology of the disease remains unknown, and under certain circumstances it is difficult for the physician to diagnose. Previous studies have shown a correlation between inflammatory biomarkers such as C-reactive protein (CRP) and FMS activity, suggesting that an inflammatory component may play a role in this disease pathogenesis.ObjectivesTo investigate the role of certain new inflammatory biomarkers in the diagnosis of patients with FMS.MethodsIn this study data were collected from FMS patients who were admitted to Ziv Medical Center during the period 2013 to 2019 in an attempt to find a connection between inflammatory markers detectable by a traditional complete blood count (CBC) tests such as neutrophil-lymphocytes ratio (NLR), platelet-lymphocyte ratio (PLR), mean platelet value (MPV), red cell distribution width (RDW), and C-reactive protein (CRP) and FMS.ResultsWe found significantly higher CRP levels, MPV, and PLR and lower lymphocyte count in the FMS group compared to the control group.ConclusionsFMS has certain inflammatory components that may be useful in disease diagnosis.

39 keywords...

hide…